

1 **Title:** COVID-19 Testing and Vaccination among US Older Adults with Vision Impairment: The
2 National Health and Aging Trends Study 2021

3
4 **Authors:** Louay Almidani, MD, MSc¹, Bonnielin K. Swenor, PhD, MPH^{2,3}, Joshua R. Ehrlich, MD,
5 MPH^{4,5}, Varshini Varadaraj, MD, MPH^{2,3}

6
7 **Affiliations**

8 ¹ Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.

9 ² Johns Hopkins Disability Health Research Center, Johns Hopkins University, Baltimore,
10 Maryland

11 ³ Johns Hopkins University School of Nursing, Baltimore, Maryland

12 ⁴ Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor

13 ⁵ Institute for Social Research, University of Michigan, Ann Arbor

14

15 **Abstract**

16 **Purpose:** To examine the associations between vision impairment (VI) and COVID-19 testing
17 and vaccination services in older US adults.

18

19 **Methods:** This cross-sectional study assessed data from adults ≥ 65 years who participated in
20 the National Health and Aging Trends Study (year 2021), a nationally representative sample of
21 Medicare beneficiaries. Exposure: Distance VI ($<20/40$), near VI ($<20/40$), contrast sensitivity
22 impairment (CSI) (<1.55 logCS), and any VI (distance, near, or CSI). Outcomes: Self-reported
23 COVID-19 testing and vaccination.

24

25 **Results:** Of 2,822 older adults, the majority were female (weighted; 55%) and White (82%), and
26 32% had any VI. In fully-adjusted regression analyses, older adults with any VI had similar
27 COVID-19 vaccination rates to adults without any VI (OR:0.77, 95% CI:0.54–1.09), but had lower
28 odds of COVID-19 testing (OR:0.82, 95% CI:0.68–0.97). Older adults with distance (OR:0.47, 95%
29 CI:0.22–0.99) and near (OR:0.68, 95% CI:0.47–0.99) VI were less likely to be vaccinated for
30 COVID-19, while those with CSI were less likely to test for COVID-19 (OR:0.76, 95% CI:0.61–
31 0.95), as compared to peers without respective impairments. The remaining associations were
32 not significant ($p>.05$).

33

34 **Conclusions and Relevance:** These findings highlight inequities in the COVID-19 pandemic
35 response for people with vision disability and emphasize the need for equitable prioritization of
36 accessibility of healthcare services for all Americans.

37 **1. Introduction**

38 COVID-19, stemming from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
39 is a significant contributor to morbidity and mortality, with the elderly population emerging as
40 the most susceptible cohort.¹ Further, older age is also often associated with an increased
41 prevalence of vision impairment (VI).² As a result, adults with VI may be at a higher risk of
42 experiencing severe COVID-19 outcomes, underscoring the importance of preventive
43 healthcare services, including vaccinations.

44
45 The development of the COVID-19 vaccine has caused a major shift during the pandemic,
46 resulting in millions of lives saved globally. Watson et al (2022) estimated that vaccinations
47 prevented over 14 million deaths from COVID-19 across 185 countries and territories.³
48 Nonetheless, the impact of vaccinations has been hindered by the inadequate vaccine
49 accessibility in certain communities.³

50
51 The COVID-19 pandemic has had a disproportionate impact on people with disabilities,
52 including those with VI.⁴ It has exacerbated existing barriers in accessing essential preventive
53 healthcare services, such as vaccination and testing.⁵ Studies have shown that adults with VI are
54 less likely to use preventive services,⁶ including lower vaccine initiation rates,⁷ and experience
55 worse health outcomes than adults without VI.⁸ Additionally, individuals with VI may face
56 challenges in navigating healthcare systems and accessing public health information, which
57 could increase their risk of COVID-19 or other illnesses.⁹

58

59 Despite these associations, previous studies lacked generalizability or only assessed one aspect
60 of vision. Vision is a complex process, and while distance visual acuity (the ability to see objects
61 at a distance) is most frequently used in research studies as a measure of visual function,¹⁰ it
62 only represents one component of visual function.¹¹ Recent findings suggest that other aspects
63 of vision, such as near visual acuity (the ability to see objects located close to the eyes, which is
64 important for tasks like reading) and contrast sensitivity (the ability to perceive differences in
65 shades and distinguish objects from their background), can also impact daily functioning.¹²⁻¹⁴

66
67 Accordingly, we utilized data from the National Health and Aging Trends Study (NHATS), a US
68 population-based, nationally representative sample of Medicare beneficiaries, to assess the
69 potential associations of three measures of vision — distance visual acuity (VA), near VA, and
70 contrast sensitivity (CS) — with COVID-19 vaccination and testing in a national sample of older
71 adults, as they are at risk of VI and worse COVID-19 outcomes.⁴

72

73 **2. Materials and Methods**

74 **2.1 Study design and participants**

75 This cross-sectional study presents data from the NHATS Round 11 (2021), a nationally
76 representative sample of Medicare beneficiaries aged ≥ 65 years in the United States.¹⁵ In-home
77 interviews and performance-based tests, including vision testing, were conducted annually
78 from approximately June to November.¹⁶ Further details regarding survey sampling design have
79 been previously described.^{15,16} Written informed consent was obtained from all participants or
80 their proxies. This secondary analysis of publicly available data was acknowledged as exempt

81 research by the institutional review board of the Johns Hopkins School of Medicine. The study
82 adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
83 reporting guidelines for cross-sectional studies.

84

85 2.2 Vision Measures

86 In 2021, the NHATS introduced three objective vision tests (distance and near VA, and CS) that
87 measured presenting binocular vision while wearing habitual correction (glasses or contacts).
88 Tests were conducted via Ridgevue Vision tablet-based tests ([ridgevue.com](https://www.ridgevue.com)), which show good
89 agreement with corresponding gold standard tests (ETDRS distance acuity, MNRead near
90 acuity, and Pelli-Robson contrast sensitivity), and enable standardized monitoring to occur in a
91 variety of settings, including at home or in rehabilitation facilities.^{17,18}

92

93 For distance VA testing, participants sat five feet away from the tablet and were instructed to
94 read five letters per screen with each subsequent screen displaying reduced letter size. For near
95 VA testing, participants held the tablet at their usual reading distance and were instructed to
96 read five letters per screen with each subsequent screen displaying smaller letters. For CS
97 testing, participants were instructed to read two letters per screen, with the tone becoming
98 lighter with each subsequent screen. Further details on how the tests were conducted have
99 been described previously.^{17,19} Distance and near VA were calculated as the logarithm of the
100 minimum angle of resolution (logMAR), with near VA accounting for reading distance. CS was
101 measured in logCS units. We assessed vision on a continuous scale; distance and near VA (per
102 0.1 logMAR), and CS (per 0.1 logCS), and on a categorical scale; distance VI (<20/40), near VI

103 (<20/40) – based on the US American Academy of Ophthalmology definitions,²⁰ – and CS
104 impairment (CSI) (<1.55), as previously defined.²¹ Any objective VI was defined as having VI in
105 either distance, near, or CS, and was taken as the primary exposure.

106

107 2.3 Outcomes

108 We examined two sets of outcomes: COVID-19 vaccination and COVID-19 testing. Participants
109 were considered to have been COVID-19 vaccinated or tested if they answered “yes” to any of
110 the following questions respectively: (1) Have you been vaccinated for COVID-19? (2) Have you
111 ever been tested for COVID-19? Outcomes were based on self-reports and were recorded in the
112 NHATS dataset as binary variables (yes/no).

113

114 2.4 Covariates

115 Demographic characteristic covariates included age (categorized into five age intervals: 70-74,
116 75-79, 80-84, 85-89, and ≥ 90 ; continuous age is not provided in the publicly available NHATS
117 data), gender (male, female), race (Non-Hispanic White, Non-Hispanic Black, Hispanic, and
118 other), education (\leq high school, some college, and \geq college graduate), living arrangements
119 (alone or not alone), and number of comorbidities (0-1, 2, 3, and ≥ 4). Comorbidities include
120 self-reported diagnoses of diabetes, hypertension, myocardial infarction, arthritis
121 (osteoarthritis or rheumatoid arthritis), osteoporosis, stroke, lung disease (such as emphysema,
122 asthma, or chronic bronchitis), cancer, and hip fracture. Covariates were included based on
123 clinical relevance and/or previous demonstration of impact on VI and preventive healthcare
124 use.

125

126 2.5 Statistical Analysis

127 In NHATS Round 11, a total of 3,817 participants were sampled, and interview data were
128 obtained by direct contact with either the participant or a proxy respondent. **Figure 1** describes
129 the analytic population. Descriptive statistics were used to characterize the participants by any
130 VI status. Comparisons were performed using Pearson's chi-squared test for categorical
131 variables and Wilcoxon rank-sum test for continuous variables.

132

133 Multivariable logistic regression models were used to investigate the association between
134 various vision measures and COVID-19 vaccination and testing. While our primary exposure was
135 any VI, we constructed separate regression models for each vision variable, including distance
136 VI, near VI, and CSI. We also assessed vision on a continuous scale; distance and near VA (per
137 0.1 logMAR), and CS (per 0.1 logCS). All analyses accounted for the NHATS complex survey
138 design and models were adjusted for age, sex, race/ethnicity, education, living arrangement,
139 and comorbidities. "Don't know" and "Refuse" responses were treated as missing values and
140 excluded from the regressions. Statistical significance was defined at $p < .05$ and 2-sided values
141 are presented. All analyses were performed using Stata/SE 16.1 (StatCorp LLC, College Station,
142 TX, USA) software.

143

144 **3. Results**

145 Among a sample of 2,822 community-dwelling older adults representing 26,182,090 older
146 adults nationally, the majority was female (55%) and White (82%), and 32% had any VI (**Table**

147 1). Of the total sample, 91% adults were vaccinated for COVID-19, and 53% had ever tested for
148 COVID-19. The prevalence of COVID-19 vaccination did not differ by any VI status, but the
149 prevalence of COVID-19 testing was 11% lower among adults with any VI than adults without
150 VI. Further, COVID-19 vaccination rates were 5% lower in adults with near VI (vs. no near VI),
151 while COVID-19 testing rates were 15% lower in adults with CSI (vs. no CSI). There were no
152 significant differences in the COVID-19 vaccination and testing rates for the other vision
153 measures (**Figure 2**).

154
155 In multivariable logistic regression analysis, older adults with any VI had similar COVID-19
156 vaccination rates compared to adults without (OR: 0.77, 95% CI: 0.54–1.09), but had lower odds
157 of testing for COVID-19 (OR: 0.82, 95% CI: 0.68–0.97) (**Table 2**). When examining individual
158 objective vision measures categorically, older adults with distance (OR: 0.47, 95% CI: 0.22–0.99)
159 and near (OR: 0.68, 95% CI: 0.47–0.99) VI had lower odds of being vaccinated, and adults with
160 CSI were less likely to test for COVID-19 (OR: 0.76, 95% CI: 0.61–0.95), than their respective
161 peers without impairments. The remaining associations were not significant ($p > .05$).

162
163 When examined on a continuous scale, adults with worse distance (OR: 0.48, 95% CI: 0.24–
164 0.96), and near (OR: 0.32, 95% CI: 0.16–0.65) VA, (per 0.1 logMAR) were less likely to be
165 vaccinated, however, only adults with worse distance VA were less likely to test for COVID-19
166 (OR: 0.41, 95% CI: 0.26–0.65). Similarly, adults with worse CS (per 0.1 logCS) were less likely to
167 test for COVID-19 (0.50, 95% CI: 0.36–0.71) but did not have differences in vaccination rates as
168 compared to peers without CSI.

169
170
171

4. Discussion

172 In a nationally representative sample of US older adults, adults with VI were less likely to get
173 vaccinated or tested for COVID-19, depending on the measure of visual function. Interestingly,
174 for each 0.1 logMAR deterioration in distance or near VA, the likelihood of seeking COVID-19
175 vaccination was reduced to less than half. Similarly, the odds of undergoing COVID-19 testing
176 were equal to or less than half per 0.1 logMAR in distance VA and 0.1 logCS in CS compared to
177 their counterparts without respective impairments. Conversely, near VA (per 0.1 logMAR)
178 trended towards lower odds of undergoing COVID-19 testing, while CS (per 0.1 logCS) trended
179 towards lower odds of vaccination, though neither reached statistical significance.

180

181 Our findings are consistent with prior studies showing that people with VI are less likely to
182 utilize COVID-19 healthcare services.^{7,22} This may be due to a range of barriers within the
183 healthcare system, such as issues with accessibility of information and services, and
184 insurance.^{4,5,23} In particular, adults with VI may experience greater difficulties with accessing
185 COVID-19 information on public websites due to poor CS and other webpage accessibility
186 challenges.⁴ Additionally, transportation to drive-through testing sites posed a significant hurdle
187 in accessing testing and vaccination services, which were exacerbated by regulations such as
188 social distancing mandates.^{4,5,23} These findings are concerning, as vaccinations are essential in
189 maintaining health, and preventing severe COVID-19-associated outcomes.²⁴ Future work is
190 needed to examine if these disparities in COVID-19 healthcare services translate to worse
191 COVID-19-related health outcomes for older adults with VI.

192

193 It is essential to recognize the challenges faced by the VI community and develop strategies to
194 promote health equity and improve access to essential healthcare services. One such strategy is
195 to move towards universal design principles, which aim to create products, environments, and
196 systems that are accessible to everyone, including people with disabilities.²⁵ By promoting
197 universal design and addressing inaccessibility, we can ensure that individuals with VI have
198 equal access to healthcare services, thereby improving their independence, health, and overall
199 well-being.

200

201 Our study has some limitations. It is unclear what is meant by “been vaccinated for COVID-19?”
202 as NHATS does not specify whether it refers to full primary vaccination or one of two doses.
203 Further, the NHATS does not specify the type of COVID-19 test used (polymerase chain reaction
204 vs. antigen), or testing location (home test vs. or testing center). It is worth noting that some
205 vision measures were associated with lower testing and vaccination, while others were not.
206 This may reflect real-world differences in how various vision measures impact individuals’
207 functioning but could also be influenced by the sample size and statistical power. Irrespective,
208 overall, these findings suggest that VI is associated with reduced utilization of COVID-19 testing
209 and vaccination services among older adults.

210

211 **5. Conclusion**

212 This study highlights the inequities in the COVID-19 pandemic response for older Americans
213 with vision disability and emphasizes the importance of prioritizing accessibility of healthcare
214 services, especially COVID-19 testing and vaccination services for all people.

216 **Acknowledgement/Financial Support:** None relevant to work presented.

217 **Conflict of Interest:** All listed authors have no conflicts of interest in any materials discussed in
218 this article.

219 **Data availability statement:** Data is publicly available at <https://nhats.org/researcher>

220

221

222 **References:**

223

- 224 1. Banerjee D. The impact of Covid-19 pandemic on elderly mental health. *Int J Geriatr*
225 *Psychiatry*. 2020;35(12):1466-1467. doi:10.1002/gps.5320
- 226 2. Almidani L, Varadaraj V, Mihailovic A, Ramulu PY. Using Objective Vision Measures to
227 Explore the Association of Vision Impairment With Cognition Among Older Adults in the
228 United States. *Am J Ophthalmol*. 2023;255:18-29. doi:10.1016/j.ajo.2023.05.020
- 229 3. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the
230 first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis*.
231 2022;22(9):1293-1302. doi:10.1016/S1473-3099(22)00320-6
- 232 4. Jo G, Habib D, Varadaraj V, et al. COVID-19 vaccine website accessibility dashboard.
233 *Disabil Health J*. 2022;15(3):101325. doi:10.1016/j.dhjo.2022.101325
- 234 5. Epstein S, Campanile J, Cerilli C, Gajwani P, Varadaraj V, Swenor BK. New obstacles
235 and widening gaps: A qualitative study of the effects of the COVID-19 pandemic on U.S.
236 adults with disabilities. *Disabil Health J*. 2021;14(3):101103.
237 doi:10.1016/j.dhjo.2021.101103
- 238 6. Assi L, Varadaraj V, Shakarchi AF, et al. Association of Vision Impairment With
239 Preventive Care Use Among Older Adults in the United States. *JAMA Ophthalmol*.
240 2020;138(12):1298. doi:10.1001/jamaophthalmol.2020.4524
- 241 7. Turner K, Nguyen OT, Alishahi Tabriz A, Islam JY, Hong YR. COVID-19 Vaccination
242 Rates Among US Adults With Vision or Hearing Disabilities. *JAMA Ophthalmol*.
243 2022;140(9):894. doi:10.1001/jamaophthalmol.2022.3041
- 244 8. Varadaraj V, Ehrlich JR, Swenor BK. Vision Impairment Has Implications for Aging and
245 Health Outcomes, Beyond Ophthalmology. *JAMA Netw Open*. 2022;5(5):e2214610.
246 doi:10.1001/jamanetworkopen.2022.14610
- 247 9. Spencer C, Frick K, Gower E, Kempen J, Wolff J. Disparities in Access to Medical Care
248 for Individuals with Vision Impairment. *Ophthalmic Epidemiol*. 2009;16(5):281-288.
249 doi:10.3109/09286580902999439

- 250 10. HAEGERSTROM-PORTNOY G, SCHNECK ME, LOTT LA, BRABYN and JA. The
251 Relation Between Visual Acuity and Other Spatial Vision Measures. *Optometry and*
252 *Vision Science*. 2000;77(12):653-662. doi:10.1097/00006324-200012000-00012
- 253 11. Varadaraj V, Ehrlich JR, Swenor BK. Vision Impairment Has Implications for Aging and
254 Health Outcomes, Beyond Ophthalmology. *JAMA Netw Open*. 2022;5(5):e2214610.
255 doi:10.1001/jamanetworkopen.2022.14610
- 256 12. Myers VS. Distance and Near Visual Acuity, Contrast Sensitivity, and Visual Fields of
257 10-Year-Old Children. *Archives of Ophthalmology*. 1999;117(1):94.
258 doi:10.1001/archopht.117.1.94
- 259 13. Varadaraj V, Munoz B, Deal JA, et al. Association of Vision Impairment With Cognitive
260 Decline Across Multiple Domains in Older Adults. *JAMA Netw Open*.
261 2021;4(7):e2117416. doi:10.1001/jamanetworkopen.2021.17416
- 262 14. Swenor BK, Simonsick EM, Ferrucci L, Newman AB, Rubin S, Wilson V. Visual
263 Impairment and Incident Mobility Limitations: The Health, Aging and Body Composition
264 Study. *J Am Geriatr Soc*. 2015;63(1):46-54. doi:10.1111/jgs.13183
- 265 15. Vicki A. Freedman, Jennifer A. Schrack, Maureen E. Skehan, and Judith D. Kasper. 2022.
266 National Health and Aging Trends Study User Guide: Rounds 1-11 Final Release.
267 Baltimore: Johns Hopkins University School of Public Health. Available at
268 www.NHATS.org. ([https://www.nhats.org/sites/default/files/2022-](https://www.nhats.org/sites/default/files/2022-11/NHATS_User_Guide_R11_Final_Release.pdf)
269 [11/NHATS_User_Guide_R11_Final_Release.pdf](https://www.nhats.org/sites/default/files/2022-11/NHATS_User_Guide_R11_Final_Release.pdf)).
- 270 16. Freedman VA, Kasper JD. Cohort Profile: The National Health and Aging Trends Study
271 (NHATS). *Int J Epidemiol*. 2019;48(4):1044-1045g. doi:10.1093/ije/dyz109
- 272 17. Hu, Mengyao, Joshua R. Ehrlich, Nicholas S. Reed, Vicki A. Freedman. 2022. National
273 Health and Aging Trends Study (NHATS) Vision and Hearing Activities User Guide.
274 Johns Hopkins University School of Public Health. Available at www.NHATS.org.
275 ([https://www.nhats.org/sites/default/files/2022-](https://www.nhats.org/sites/default/files/2022-07/NHATS%20Vision%20and%20Hearing%20Activities%20User%20Guide.pdf)
276 [07/NHATS%20Vision%20and%20Hearing%20Activities%20User%20Guide.pdf](https://www.nhats.org/sites/default/files/2022-07/NHATS%20Vision%20and%20Hearing%20Activities%20User%20Guide.pdf)).
- 277 18. Varadaraj V, Assi L, Gajwani P, et al. Evaluation of Tablet-Based Tests of Visual Acuity
278 and Contrast Sensitivity in Older Adults. *Ophthalmic Epidemiol*. 2021;28(4):293.
279 doi:10.1080/09286586.2020.1846758

- 280 19. Hu M, Freedman VA, Ehrlich JR, Reed NS, Billington C, Kasper JD. Collecting
281 Objective Measures of Visual and Auditory Function in a National in-Home Survey of
282 Older Adults. *J Surv Stat Methodol*. 2021;9(2):309-334. doi:10.1093/JSSAM/SMAA044
- 283 20. Low Vision - American Academy of Ophthalmology. Accessed April 10, 2023.
284 <https://www.aaof.org/education/low-vision-and-vision-rehab>
- 285 21. Mäntyjärvi M, Laitinen T. Normal values for the Pelli-Robson contrast sensitivity test. *J*
286 *Cataract Refract Surg*. 2001;27(2):261-266. doi:10.1016/S0886-3350(00)00562-9
- 287 22. Ryerson AB, Rice CE, Hung MC, et al. Disparities in COVID-19 Vaccination Status,
288 Intent, and Perceived Access for Noninstitutionalized Adults, by Disability Status —
289 National Immunization Survey Adult COVID Module, United States, May 30–June 26,
290 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(39):1365-1371.
291 doi:10.15585/mmwr.mm7039a2
- 292 23. Shalaby WS, Odayappan A, Venkatesh R, et al. The Impact of COVID-19 on Individuals
293 Across the Spectrum of Visual Impairment. *Am J Ophthalmol*. 2021;227:53-65.
294 doi:10.1016/j.ajo.2021.03.016
- 295 24. Yuan Y, Thierry JM, Bull-Otterson L, et al. COVID-19 Cases and Hospitalizations
296 Among Medicare Beneficiaries With and Without Disabilities — United States, January 1,
297 2020–November 20, 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71(24):791-796.
298 doi:10.15585/mmwr.mm7124a3
- 299 25. Samuel LJ, Xiao E, Cerilli C, et al. The development of the Supplemental Nutrition
300 Assistance Program enrollment accessibility (SNAP-access) score. *Disabil Health J*.
301 2022;15(4):101366. doi:10.1016/j.dhjo.2022.101366


302
303

NHATS Round 11 (2021) participants
(n=3,817)

Excluded:
Deceased participants **(n=351)**
Nursing home residents **(n=218)**
Participants who did not attempt any vision
activities **(n=391)**
Participants with missing visual acuity or
contrast sensitivity data **(n=35)**

Participants with complete vision data and
COVID-19 data **(n=2,822)**

COVID-19 Vaccination



COVID-19 Testing

